Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter P Toth

Showing results (141-150 of 425) with videos related to

Pageof 43
Sort By:
Vascular Health and Risk Management|November 21, 2012
Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markersElaine Chiquette, Peter P Toth, Gilbert Ramirez, et al.
Vascular Health and Risk Management|February 11, 2012
Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapyPeter P Toth, Kamlesh M Thakker, Ping Jiang, et al.
Vascular Health and Risk Management|June 9, 2016
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabDirk J Blom, Ricardo Dent, Rita C Castro, et al.
Journal of Clinical Lipidology|August 19, 2017
Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gapsKevin C Maki, Orsolya M Palacios, Marjorie Bell, et al.
Expert Opinion on Pharmacotherapy|December 7, 2018
Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in childrenDragana Nikolic, Andreea Corina, Peter P Toth, et al.
Diabetes Care|October 3, 2019
Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014Wenjun Fan, Sephy Philip, Craig Granowitz, et al.
The American Journal of Cardiology|September 16, 2020
REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES])Nathan D Wong, Wenjun Fan, Sephy Philip, et al.
Journal of Clinical Lipidology|May 24, 2011
Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial HypercholesterolemiaPaul N Hopkins, Peter P Toth, Christie M Ballantyne, et al.
Expert Review of Cardiovascular Therapy|March 13, 2010
Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarkerPeter P Toth, Peter A McCullough, Michael S Wegner, et al.
Cardiology Journal|November 9, 2019
Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007-2014Wenjun Fan, Sephy Philip, Peter P Toth, et al.
Pageof 43

Showing results (141-150 of 425) with videos related to

Sort By:
Pageof 43
Vascular Health and Risk Management|November 21, 2012
Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markersElaine Chiquette, Peter P Toth, Gilbert Ramirez, et al.
Vascular Health and Risk Management|February 11, 2012
Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapyPeter P Toth, Kamlesh M Thakker, Ping Jiang, et al.
Vascular Health and Risk Management|June 9, 2016
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabDirk J Blom, Ricardo Dent, Rita C Castro, et al.
Journal of Clinical Lipidology|August 19, 2017
Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gapsKevin C Maki, Orsolya M Palacios, Marjorie Bell, et al.
Expert Opinion on Pharmacotherapy|December 7, 2018
Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in childrenDragana Nikolic, Andreea Corina, Peter P Toth, et al.
Diabetes Care|October 3, 2019
Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014Wenjun Fan, Sephy Philip, Craig Granowitz, et al.
The American Journal of Cardiology|September 16, 2020
REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES])Nathan D Wong, Wenjun Fan, Sephy Philip, et al.
Journal of Clinical Lipidology|May 24, 2011
Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial HypercholesterolemiaPaul N Hopkins, Peter P Toth, Christie M Ballantyne, et al.
Expert Review of Cardiovascular Therapy|March 13, 2010
Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarkerPeter P Toth, Peter A McCullough, Michael S Wegner, et al.
Cardiology Journal|November 9, 2019
Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007-2014Wenjun Fan, Sephy Philip, Peter P Toth, et al.
Pageof 43